SCHEMBL14714654

SCHEMBL14714654

COC(OC)c1ccc(C#Cc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 8/20 0.53
RARG P13631 8/20 0.53
RARA P10276 5/20 0.48
CYP26A1 O43174 1/20 0.48
CYP3A4 P08684 1/20 0.48
CRABP2 P29373 1/20 0.48
PTPN11 Q06124 2/20 0.46
ACACB O00763 2/20 0.46
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
RXRA P19793 1/20 0.42
RXRB P28702 1/20 0.42
FFAR1 O14842 1/20 0.41
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41
CA12 O43570 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA7 P43166 1/20 0.41
TPMT P51580 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3876089 0.89 CA1 (0.54) CA1CA2RXRARXRBTP53
Bromide SCHEMBL10487161 0.87 CA1 (0.52) CA1CA2RXRARXRBTP53
SCHEMBL6715937 0.84 RXRA (0.53) CA1CA2RXRARXRBTP53
SCHEMBL14714748 0.80 CA1 (0.50) CYP3A4ACACBCA1CA2CA12
SCHEMBL29789030 0.79 RARB (0.69) RARBRARGRARACYP26A1CYP3A4
SCHEMBL69572 0.79 RARB (0.69) RARBRARGRARACYP26A1CYP3A4
SCHEMBL18712171 0.78 RARB (0.55) RARBRARGRARACYP26A1CYP3A4
SCHEMBL25694178 0.77 FFAR1 (0.43) ACACBFFAR1
Hydrochloric Acid SCHEMBL5666955 0.77 RARB (0.67) RARBRARGRARACYP26A1CYP3A4
SCHEMBL7703160 0.77 CA1 (0.77) RARBRARGRARACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2562155-B1 HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2019-06-05 EP disclosed
EP-2562155-B1 HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2019-06-05 EP disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
CN-103003233-B Novel hydroxamic acid derivative TAISHO PHARMACEUTICAL CO.,LTD. (JP) 2016-03-16 CN disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
CN-103003233-A Novel hydroxamic acid derivative TAISHO PHARMACEUTICAL CO LTD 2013-03-27 CN disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 EP disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 RARB 2653/4885RARG 3346/4885RARA 2680/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 RARB 2653/4885RARG 3346/4885RARA 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.